366 related articles for article (PubMed ID: 15655933)
1. Pemetrexed in malignant pleural mesothelioma.
Gatzemeier U
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of pemetrexed for the treatment of malignant mesothelioma.
Kindler HL
Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):49-53. PubMed ID: 15339060
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
Manegold C
Semin Oncol; 2003 Aug; 30(4 Suppl 10):32-6. PubMed ID: 12917819
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
Budde LS; Hanna NH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed for diffuse malignant pleural mesothelioma.
Manegold C; Aisner J
Semin Oncol; 2002 Apr; 29(2 Suppl 5):30-5. PubMed ID: 12023790
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
11. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
12. [Update of pemetrexed in thoracic oncology].
Brechot JM; Morère JF
Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
Suwanrusme H; Meyer ML; Green MR
Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S56-60. PubMed ID: 15117426
[TBL] [Abstract][Full Text] [Related]
14. Standard therapy for the treatment of malignant pleural mesothelioma.
Vogelzang NJ
Lung Cancer; 2005 Oct; 50 Suppl 1():S23-4. PubMed ID: 16291429
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer.
Scagliotti GV; Novello S; Crino L; Rosell R
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):32-7. PubMed ID: 15655934
[TBL] [Abstract][Full Text] [Related]
16. Second-line treatment for malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
Fizazi K; John WJ; Vogelzang NJ
Semin Oncol; 2002 Feb; 29(1):77-81. PubMed ID: 11836672
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed in second-line treatment of non-small-cell lung cancer.
De Marinis F; De Petris L
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):38-42. PubMed ID: 15655935
[TBL] [Abstract][Full Text] [Related]
19. FDA drug approval summaries: pemetrexed (Alimta).
Hazarika M; White RM; Johnson JR; Pazdur R
Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed in advanced NSCLC: a review of the clinical data.
Zinner RG; Fossella FV; Herbst RS
Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):54-62. PubMed ID: 15339061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
